<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://salt.semanticauthoring.org/ontologies/sdo#hasParagraph>	<http://linked.opendata.cz/resource/sukl/spc/paragraph/SPC101295_doc-4-5-1> .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://salt.semanticauthoring.org/ontologies/sdo#hasParagraph>	<http://linked.opendata.cz/resource/sukl/spc/paragraph/SPC101295_doc-4-5-2> .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://salt.semanticauthoring.org/ontologies/sdo#hasParagraph>	<http://linked.opendata.cz/resource/sukl/spc/paragraph/SPC101295_doc-4-5-3> .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://salt.semanticauthoring.org/ontologies/sdo#hasSectionTitle>	"4.5. Interakce s\u00A0jin\u00FDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky a jin\u00E9 formy interakce"@cs .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://salt.semanticauthoring.org/ontologies/sdo#hasOrderNumber>	"004.005" .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://salt.semanticauthoring.org/ontologies/sdo#Section> .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://linked.opendata.cz/ontology/spc/InteractionSection> .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC101295_doc-4-5>	<http://salt.semanticauthoring.org/ontologies/sdo#hasText>	"Absorbce n\u011Bkter\u00FDch l\u00E9\u010Div (ketokonazolu, amoxicilinu, prepar\u00E1ty se \u017Eelezem) z\u00E1vis\u00ED na kyselosti \u017Ealude\u010Dn\u00ED \u0161\u0165\u00E1vy. Famotidin sni\u017Euje kyselost \u017Ealude\u010Dn\u00ED \u0161\u0165\u00E1vy a proto by m\u011Bl b\u00FDt u\u017Eit nejm\u00E9n\u011B 2 hodiny po pod\u00E1n\u00ED t\u011Bchto l\u00E1tek. Sou\u010Dasn\u00E9 u\u017E\u00EDv\u00E1n\u00ED ostatn\u00EDch inhibitor\u016F H2 \u2013receptor\u016F m\u016F\u017Ee v\u00FDznamn\u011B sni\u017Eovat \u00FA\u010Dinnost tolazolinu. A\u010Dkoli nebyla prok\u00E1z\u00E1na \u017E\u00E1dn\u00E1 interakce famotidinu s\u00A0tolazolinem, m\u016F\u017Ee se projevit a proto by \u00FA\u010Dinnost tolazolinu m\u011Bla b\u00FDt ov\u011B\u0159ena na za\u010D\u00E1tku konkomitantn\u00ED l\u00E9\u010Dby nebo p\u0159i jej\u00EDm p\u0159eru\u0161en\u00ED. Pokud se prok\u00E1\u017Ee sn\u00ED\u017Een\u00ED \u00FA\u010Dinnosti tolazolinu, m\u011Bla by b\u00FDt opatrn\u011B zv\u00FD\u0161ena jeho d\u00E1vka nebo p\u0159eru\u0161ena l\u00E9\u010Dba famotidinem.\nPotrava a antacida v\u00FDznamn\u011B neovliv\u0148uj\u00ED l\u00E9\u010Dbu famotidinem.\nFamotidin neovliv\u0148uje jatern\u00ED oxid\u00E1zov\u00FD syst\u00E9m cytochromu P- 450, tak\u017Ee nenaru\u0161uje metabolismus or\u00E1ln\u00EDch antikoagulanci\u00ED, antipyrinu, aminopyrinu, theofylinu, fenytoinu, diazepamu, ethanolu a propranololu.\n"@cs .